Skip to content

QuidelOrtho Corporation QDEL Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$17.8M-168%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Zoetis logo
ZoetisZTS

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$921.94M-51.4%
Enterprise value$3.88B-20.1%
P/S0.4×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
QuidelOrtho Corporation (QDEL) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of -$29.4M in Q1 2026.
How has QuidelOrtho Corporation's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
QuidelOrtho Corporation's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 202.4% year-over-year, from $28.7M to -$29.4M.
What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
Represents the net change in the total cash position, including restricted cash, over a specific reporting period after accounting for operating, investing, and financing activities. It serves as the primary indicator of the company's overall liquidity health and cash generation capability.